Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 5 | 1 | — | — | 6 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 4 | 1 | — | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | — | — | — | 2 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
Adenocarcinoma | D000230 | — | — | — | 1 | — | — | — | 1 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 1 | — | — | — | 1 |
Drug common name | Tusamitamab ravtansine |
INN | tusamitamab ravtansine |
Description | Tusamitamab ravtansine is an antibody pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Antibody |
Drug class | monoclonal antibodies; maytansinoid derivatives |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4298098 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | DSS3BE2ZXN (ChemIDplus, GSRS) |